retatrutide phase 2 trial obesity type 2 diabetes is investigational and is not FDA approved. In TRANSCEND retatrutide phase 2 trial obesity

BENEFITS: Regulates mitochondrial function

The first couple months lost a bit more, 2.0lb/wk and then we slowly dropped the dose a bit until the 1lb weekly was happening

Understanding whether combination therapy or monotherapy suits your individual biology requires more than clinical guidelines alone

doi: 10.1172/JCI146353 Summary Keywords GIP, GLP-1, tirzepatide, basal insulin, type 2 diabetes, obesity, body weight, hypoglycemia Citation Lisco G, De Tullio A, Disoteo O, De Geronimo V, Piazzolla G, De Pergola G, Giagulli VA, Jirillo E, Guastamacchia E, Sabb C and Triggiani V (2022) Basal insulin intensification with GLP-1RA and dual GIP and GLP-1RA in patients with uncontrolled type 2 diabetes mellitus: A rapid review of randomized controlled trials and meta-analysis

Asociado al TB-500 (cicatrizacin) y al KPV (antiinflamacin cutnea), el blend podra favorecer los procesos de reparacin de la piel